ArticleAmerican journal of cancer research2015

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Jessica D Sun et al.PubMed ↗Full text ↗

No numbers read from the abstract.